يعرض 1 - 10 نتائج من 19 نتيجة بحث عن '"Gaudy, Allison"', وقت الاستعلام: 0.61s تنقيح النتائج
  1. 1
    دورية
    Safety, Pharmacokinetics, and Antifibrotic Activity of CC‐90001 (BMS‐986360), a c‐Jun N‐Terminal Kinase Inhibitor, in Pulmonary Fibrosis

    المؤلفون: Horan, Gerald, Ye, Ying, Adams, Mary, Parton, Anastasia, Cedzik, Dorota, Tang, Shaojun, Brown, Elizabeth A., Liu, Liangang, Nissel, Jim, Carayannopoulos, Leonidas N., Gaudy, Allison, Schafer, Peter, Palmisano, Maria, Ramirez‐Valle, Francisco

    المصدر: Clinical Pharmacology in Drug Development; August 2023, Vol. 12 Issue: 8 p779-789, 11p


    أضف إلى المفضلة
  2. 2
    دورية
    Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide

    المؤلفون: Cheng, Yiming, Gaudy, Allison, Liu, Liangang, Ye, Ying, Thomas, Michael, Xue, Yongjun, Zhou, Simon, Li, Yan

    المصدر: Clinical Pharmacology in Drug Development; August 2023, Vol. 12 Issue: 8 p819-825, 7p


    أضف إلى المفضلة
  3. 3
    دورية
    Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants

    المؤلفون: Ye, Ying, Gaudy, Allison, Thomas, Michael, Reyes, Josephine, Burkhardt, Barbara, Horan, Gerald, Liu, Liangang, Chen, Jian, Ghosh, Atalanta, Carayannopoulos, Leonidas N., Tatosian, Daniel A., Palmisano, Maria

    المصدر: Clinical Pharmacology in Drug Development; December 2022, Vol. 11 Issue: 12 p1394-1404, 11p


    أضف إلى المفضلة
  4. 4
    دورية
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

    المؤلفون: Wong, Sandy W., Bar, Noffar, Paris, Laura, Hofmeister, Craig C, Hansson, Markus, Santoro, Armando, Mateos, Maria-Victoria, Rodríguez-Otero, Paula, Lund, Johan, Encinas, Cristina, Yee, Andrew J., Oriol, Albert, Cerchione, Claudio, de la Rubia, Javier, Ferstl, Barbara, Carlson, Kristina, Ribas, Paz, Bermúdez, Arancha, Boss, Isaac W., Gaudy, Allison, Li, Shaoyi, Hsu, Kevin, Godwin, Colin D., Burgess, Michael R., San-Miguel, Jesús, Costa, Luciano J.

    المصدر: Blood; November 2022, Vol. 140 Issue: Supplement 1 p400-402, 3p

    النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

    المؤلفون: Wong, Sandy W., Bar, Noffar, Paris, Laura, Hofmeister, Craig C, Hansson, Markus, Santoro, Armando, Mateos, Maria-Victoria, Rodríguez-Otero, Paula, Lund, Johan, Encinas, Cristina, Yee, Andrew J., Oriol, Albert, Cerchione, Claudio, de la Rubia, Javier, Ferstl, Barbara, Carlson, Kristina, Ribas, Paz, Bermúdez, Arancha, Boss, Isaac W., Gaudy, Allison, Li, Shaoyi, Hsu, Kevin, Godwin, Colin D., Burgess, Michael R., San-Miguel, Jesús, Costa, Luciano J.

    المصدر: Blood; November 2022, Vol. 140 Issue: 1, Number 1 Supplement 1 p400-402, 3p

    النص الكامل

    أضف إلى المفضلة
  6. 6
    دورية
    Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial

    المؤلفون: Niemeyer, Charlotte M., Flotho, Christian, Lipka, Daniel B., Starý, Jan, Rössig, Claudia, Baruchel, André, Klingebiel, Thomas, Micalizzi, Concetta, Michel, Gérard, Nysom, Karsten, Rives, Susana, Schmugge Liner, Markus, Zecca, Marco, Schönung, Maximilian, Baumann, Irith, Nöllke, Peter, Benettaib, Bouchra, Biserna, Noha, Poon, Jennifer, Simcock, Mathew, Patturajan, Meera, Menezes, Daniel, Gaudy, Allison, van den Heuvel-Eibrink, Marry M., Locatelli, Franco

    المصدر: Blood Advances; July 2021, Vol. 5 Issue: 14 p2901-2908, 8p

    النص الكامل

    أضف إلى المفضلة
  7. 7
    دورية
    Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial

    المؤلفون: Niemeyer, Charlotte M., Flotho, Christian, Lipka, Daniel B., Starý, Jan, Rössig, Claudia, Baruchel, André, Klingebiel, Thomas, Micalizzi, Concetta, Michel, Gérard, Nysom, Karsten, Rives, Susana, Schmugge Liner, Markus, Zecca, Marco, Schönung, Maximilian, Baumann, Irith, Nöllke, Peter, Benettaib, Bouchra, Biserna, Noha, Poon, Jennifer, Simcock, Mathew, Patturajan, Meera, Menezes, Daniel, Gaudy, Allison, van den Heuvel-Eibrink, Marry M., Locatelli, Franco

    المصدر: Blood Advances; July 2021, Vol. 5 Issue: 14 p2901-2908, 8p

    النص الكامل

    أضف إلى المفضلة
  8. 8
    دورية
    First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator

    المؤلفون: Ye, Ying, Gaudy, Allison, Schafer, Peter, Thomas, Michael, Weiss, Daniel, Chen, Nianhang, Liu, Liangang, Xue, Yongjun, Carayannopoulos, Leon, Palmisano, Maria

    المصدر: Clinical Pharmacology in Drug Development; May 2021, Vol. 10 Issue: 5 p471-485, 15p


    أضف إلى المفضلة
  9. 9
    دورية
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

    المؤلفون: Bar, Noffar, Mateos, Maria Victoria, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig C., Rodriguez Otero, Paula, Bermúdez, Maria Aranzazu, Martin, Thomas, Santoro, Armando, Yee, Andrew J., Creignou, Maria, Encinas Rodriguez, Cristina, Cerchione, Claudio, De La Rubia, Javier, Oriol, Albert, Waibel, Heidi, Besemer, Britta, Thompson, Ethan, Kiesel, Brian, Chen, Jinjie, Chung, Alexander, Boss, Isaac W., Gaudy, Allison, Li, Shaoyi, Hsu, Kevin, Godwin, Colin, Burgess, Michael R., San-Miguel, Jesús, Costa, Luciano

    المصدر: Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p2011-2011, 1p


    أضف إلى المفضلة
  10. 10
    دورية
    Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

    المؤلفون: Boss, Isaac W., Thompson, Ethan, Gaudy, Allison M., Vu, Minh Diem, Godwin, Colin D., Burgess, Michael R., Wong, Sandy W., Costa, Luciano J.

    المصدر: Blood; November 2022, Vol. 140 Issue: Supplement 1 p7116-7117, 2p

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث